Clinical Trial

Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 2, 2024 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this type of clinical trial study is to evaluate the safety and efficacy of metabolic remodeling nature killer cells as neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer
Trial Details
NCT Number NCT06395844
Lead Sponsor Anhui Provincial Cancer Hospital
Collaborators: Anhui Kecheng intelligent health technology Co., LTD
Conditions Ovarian Cancer
Enrollment 28 participants
Start Date 2024-05-01
Primary Completion 2025-05-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-02